Group 1 - Fuhong Hanlin (02696) shares rose over 5%, reaching a new historical high of 81.35 HKD, with a trading volume of 178 million HKD [1] - The World Lung Cancer Conference (WCLC) announced that Fuhong Hanlin had 10 lung cancer studies selected, including 4 oral presentations and 2 poster presentations, covering key clinical scenarios in non-squamous/squamous non-small cell lung cancer (nsNSCLC/sqNSCLC) and extensive small cell lung cancer (ES-SCLC) [1] - The selected studies focus on three core innovative drugs: anti-PD-1 monoclonal antibody H drug Hanshu (Sru Li monoclonal antibody), anti-EGFR monoclonal antibody HLX07, and the world's first PD-L1 ADC HLX43 entering Phase II clinical trials [1] Group 2 - Citigroup anticipates that Fuhong Hanlin will present the latest data on HLX43 at the WCLC, which will further reveal its potential in treating non-small cell lung cancer (NSCLC) [2] - If HLX43 maintains an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in a larger sample, the data will be highly persuasive [2] - Citigroup estimates that the global study for third-line NSCLC treatment could start as early as the first half of 2026, with a risk-adjusted peak sales estimate for HLX43 reaching around 2.3 billion USD, indicating potential for further upside if more data is obtained [2]
复宏汉霖涨逾5%再创新高 三款核心产品亮相WCLC 花旗称关注HLX43最新数据